LeonaBio, Inc. — Form SCHEDULE 13D/A
Filed October 28, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Sermonix Pharmaceuticals filed an amended Schedule 13D/A on October 28, 2026 regarding its beneficial ownership of LeonaBio, Inc. The filing provides no specific details about share counts, percentages, dollar amounts, transaction dates, or what changed from the original disclosure. The document is a procedural amendment but lacks substantive disclosure of the actual ownership position or any triggering event.
Why this rating
Amendment to ownership disclosure with no disclosed specifics. Insufficient material detail to assess impact on $9.9M company. Routine Schedule 13D amendment filing.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.